Startseite Kongressberichte 2020 All-Virtual 62nd ASH Annual Meeting and Exposition Oral Sessions Acute Myeloid Leukemia AML - Novel Therapy, excluding Transplantation III

616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Advances in immunotherapeutics for management of AML

Watch Session

165 A Phase I Study of Lintuzumab Ac225 in Combination with CLAG-M Chemotherapy in Relapsed/Refractory AML

Sameem Abedin, Guru Subramanian Guru Guru Murthy, Mehdi Hamadani, et al.

 

166 A WT-1 and PRAME “Fast-DC” Immunotherapy As a Potential Post-Remission Strategy for AML

Yngvar Floisand, Iris Bigalke, Dag Josefsen, et al.

 

167 Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Naveen Pemmaraju, Giovanni Martinelli, Elisabetta Todisco, et al.

 

168 Conversion from MRD Positive to Negative Status in AML Patients in CR1 after Treatment with an Allogeneic Leukemia-Derived Dendritic Cell Vaccine

Arjan van de Loosdrecht, Janine van Elssen, Bjørn Tore Gjertsen, et al.

 

169 Overexpression of CD200 Is a Stem Cell-Specific Mechanism of Immune Escape in AML

Shelley Herbrich, Natalia Baran, Gheath Alatrash, et al.

 

170 Safety and Efficacy of Decitabine Plus Ipilimumab in Relapsed or Refractory MDS/AML in the Post-BMT or Transplant Naïve Settings according to ASH clinically relevant abstract

Jacqueline S. Garcia, Yael Flamand, Benjamin K. Tomlinson, et al.